Close Menu

NEW YORK (GenomeWeb) – Leerink today initiated coverage of HTG Molecular with an Outperform rating for its stock and a target price of $6 per share.

In a note to investors, analyst Puneet Souda said that HTG has a growing funnel of biopharma partnerships and projects that have the potential to convert to US Food and Drug Administration-approved companion diagnostics and drive "significant revenue upside."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.